Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antibodies, Viral"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 42992
Tytuł:
Distinguishing features of long COVID identified through immune profiling.
Autorzy:
Klein J; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Wood J; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jaycox JR; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Dhodapkar RM; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.; Department of Ophthalmology, USC Keck School of Medicine, Los Angeles, CA, USA.
Lu P; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Gehlhausen JR; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Tabachnikova A; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Greene K; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Tabacof L; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Malik AA; Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA.
Silva Monteiro V; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Silva J; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Kamath K; SerImmune, Goleta, CA, USA.
Zhang M; SerImmune, Goleta, CA, USA.
Dhal A; SerImmune, Goleta, CA, USA.
Ott IM; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Valle G; Department of Internal Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, New Haven, CT, USA.
Peña-Hernández M; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.; Department of Microbiology, Yale School of Medicine, New Haven, CT, USA.
Mao T; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Bhattacharjee B; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Takahashi T; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Lucas C; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.
Song E; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
McCarthy D; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Breyman E; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tosto-Mancuso J; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dai Y; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Perotti E; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Akduman K; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Tzeng TJ; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Xu L; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Geraghty AC; Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA.
Monje M; Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Yildirim I; Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA.; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.; Department of Pediatrics (Infectious Diseases), Yale New Haven Hospital, New Haven, CT, USA.; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Shon J; SerImmune, Goleta, CA, USA.
Medzhitov R; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Lutchmansingh D; Department of Internal Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, New Haven, CT, USA.
Possick JD; Department of Internal Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, New Haven, CT, USA.
Kaminski N; Department of Internal Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, New Haven, CT, USA.
Omer SB; Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA.; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.; Department of Internal Medicine (Infectious Diseases), Yale School of Medicine, New Haven, CT, USA.
Krumholz HM; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.; Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
Guan L; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.; Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
Dela Cruz CS; Department of Internal Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, New Haven, CT, USA.; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.
van Dijk D; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA. .; Department of Computer Science, Yale University, New Haven, CT, USA. .; Department of Internal Medicine (Cardiology), Yale School of Medicine, New Haven, CT, USA. .
Ring AM; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA. .; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA. .
Putrino D; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .; Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .
Iwasaki A; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA. .; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA. .; Howard Hughes Medical Institute, Chevy Chase, MD, USA. .
Pokaż więcej
Źródło:
Nature [Nature] 2023 Nov; Vol. 623 (7985), pp. 139-148. Date of Electronic Publication: 2023 Sep 25.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/blood
Antibodies, Viral*/immunology
Herpesvirus 4, Human*/immunology
Hydrocortisone*/blood
Lymphocytes*/immunology
Myeloid Cells*/immunology
Post-Acute COVID-19 Syndrome*/diagnosis
Post-Acute COVID-19 Syndrome*/immunology
Post-Acute COVID-19 Syndrome*/physiopathology
Post-Acute COVID-19 Syndrome*/virology
SARS-CoV-2*/immunology
Humans ; Biomarkers/blood ; Cross-Sectional Studies ; Immunophenotyping ; Machine Learning
Czasopismo naukowe
Szczegóły
Tytuł:
Omicron BA.2.86 cross-neutralising activity in community sera from the UK.
Autorzy:
Willett BJ; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Logan N; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Scott S; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Davis C; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
McSorley T; Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.
Asamaphan P; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Hosie MJ; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Olmo P; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Grove J; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Orton R; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Ho A; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Haughney J; Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.
Robertson DL; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Thomson EC; MRC University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK; Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK. Electronic address: .
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2023 Dec 02; Vol. 402 (10417), pp. 2075-2076. Date of Electronic Publication: 2023 Nov 09.
Typ publikacji:
Letter
MeSH Terms:
Antibodies, Viral*
Antibodies, Neutralizing*
Humans ; United Kingdom
Opinia redakcyjna
Szczegóły
Tytuł:
Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities.
Autorzy:
Wang L; Department of Infectious Disease, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.; Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Li C; Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Li W; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Nanjing, People's Republic of China.
Zhao L; Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Zhao T; Department of Infectious Disease, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Chen L; Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
Li M; Department of Infectious Disease, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Fan J; Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Li J; Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Wu C; Department of Infectious Disease, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
Chen Y; Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, People's Republic of China.
Pokaż więcej
Źródło:
Emerging microbes & infections [Emerg Microbes Infect] 2023 Dec; Vol. 12 (2), pp. 2225640.
Typ publikacji:
Journal Article
MeSH Terms:
Phagocytosis*
Antibodies, Viral*
Humans ; Breakthrough Infections ; Vaccines, Inactivated ; Immunoglobulin G ; Antibodies, Neutralizing
Czasopismo naukowe
Szczegóły
Tytuł:
Engineered immunogens to elicit antibodies against conserved coronavirus epitopes.
Autorzy:
Kapingidza AB; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Marston DJ; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Harris C; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Wrapp D; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Winters K; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Mielke D; Department of Surgery, Duke University, Durham, NC, USA.; Center for Human Systems Immunology, Duke University, Durham, NC, USA.
Xiaozhi L; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Yin Q; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Foulger A; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Parks R; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Barr M; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Newman A; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Schäfer A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Eaton A; Department of Surgery, Duke University, Durham, NC, USA.
Flores JM; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Harner A; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Catanzaro NJ Jr; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mallory ML; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mattocks MD; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Beverly C; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Rhodes B; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Mansouri K; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
Van Itallie E; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Vure P; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Dunn B; Department of Surgery, Duke University, Durham, NC, USA.
Keyes T; Department of Surgery, Duke University, Durham, NC, USA.
Stanfield-Oakley S; Department of Surgery, Duke University, Durham, NC, USA.
Woods CW; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.; Center for Infectious Diseases and Diagnostic Innovation, Duke University Medical Center, Durham, NC, USA.
Petzold EA; Center for Infectious Diseases and Diagnostic Innovation, Duke University Medical Center, Durham, NC, USA.
Walter EB; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Pediatrics, Duke University, Durham, NC, USA.
Wiehe K; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Edwards RJ; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Montefiori DC; Department of Surgery, Duke University, Durham, NC, USA.
Ferrari G; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA.; Center for Human Systems Immunology, Duke University, Durham, NC, USA.; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA.
Baric R; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Cain DW; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.
Saunders KO; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Surgery, Duke University, Durham, NC, USA.; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA.; Department of Immunology, Duke University, Durham, NC, USA.
Haynes BF; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.; Department of Medicine, Duke University, Durham, NC, USA.; Department of Immunology, Duke University, Durham, NC, USA.
Azoitei ML; Duke Human Vaccine Institute, Duke University, Durham, NC, USA. .; Department of Medicine, Duke University, Durham, NC, USA. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2023 Nov 30; Vol. 14 (1), pp. 7897. Date of Electronic Publication: 2023 Nov 30.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*
SARS-CoV-2*
Humans ; Animals ; Mice ; Epitopes ; Immunodominant Epitopes ; Peptides ; Spike Glycoprotein, Coronavirus ; Antibodies, Neutralizing
Czasopismo naukowe
Szczegóły
Tytuł:
Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up.
Autorzy:
Recanatini C; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. .
GeurtsvanKessel CH; Viroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands.
Pas SD; Microvida Laboratory for Medical Microbiology, Bravis Hospital, Roosendaal, The Netherlands.; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Broens EM; Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Maas M; Department of Internal Medicine, Bernhoven Hospital, Uden, The Netherlands.
van Mansfeld R; Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Mutsaers-van Oudheusden AJG; Department of Infection Control, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
van Rijen M; Department of Infection Control, Amphia Hospital, Breda, The Netherlands.
Schippers EF; Department of Internal Medicine, Haga Hospital, The Hague, The Netherlands.
Stegeman A; Department of Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Tami A; Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Veldkamp KE; Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Visser H; Department of Internal Medicine, Beatrix Hospital, Gorinchem, The Netherlands.
Voss A; Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Wegdam-Blans MCA; Catharina Hospital, Eindhoven, The Netherlands.; Hospital St. Jans Gasthuis, Weert, The Netherlands.; Department of Medical Microbiology, Stichting PAMM, Veldhoven, The Netherlands.
Wertheim HFL; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Wever PC; Department of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
Koopmans MPG; Viroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands.
Kluytmans JAJW; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Infection Control, Amphia Hospital, Breda, The Netherlands.; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Kluytmans-van den Bergh MFQ; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Infection Control, Amphia Hospital, Breda, The Netherlands.; Amphia Academy Infectious Disease Foundation, Amphia Hospital, Breda, The Netherlands.
Pokaż więcej
Corporate Authors:
COCON Study Group
Źródło:
Antimicrobial resistance and infection control [Antimicrob Resist Infect Control] 2023 Nov 29; Vol. 12 (1), pp. 137. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Antibodies, Viral*/blood
COVID-19*/epidemiology
Humans ; Cross-Sectional Studies ; Diabetes Mellitus ; Fatigue ; Follow-Up Studies ; Health Personnel ; Hospitals ; Pain ; Prospective Studies ; Retrospective Studies ; Seroepidemiologic Studies ; Netherlands
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The solution structure of the heavy chain-only C5-Fc nanobody reveals exposed variable regions that are optimal for COVID-19 antigen interactions.
Autorzy:
Gao X; Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom.
Thrush JW; Department of Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus, Didcot, United Kingdom.
Gor J; Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom.
Naismith JH; Department of Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus, Didcot, United Kingdom.
Owens RJ; Department of Structural Biology, The Rosalind Franklin Institute, Harwell Science Campus, Didcot, United Kingdom.
Perkins SJ; Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom. Electronic address: .
Pokaż więcej
Źródło:
The Journal of biological chemistry [J Biol Chem] 2023 Nov; Vol. 299 (11), pp. 105337. Date of Electronic Publication: 2023 Oct 12.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoglobulin Heavy Chains*/chemistry
SARS-CoV-2*
Antibodies, Viral*/chemistry
Humans ; Immunoglobulin G/chemistry ; Models, Molecular ; Polysaccharides ; Single-Domain Antibodies/chemistry
Czasopismo naukowe
Szczegóły
Tytuł:
Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin.
Autorzy:
Santos RI; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Ilinykh PA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Pietzsch CA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Ronk AJ; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Huang K; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Kuzmina NA; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Zhou F; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA.
Crowe JE; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: .
Bukreyev A; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Galveston National Laboratory, Galveston, TX, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: .
Pokaż więcej
Źródło:
Cell reports [Cell Rep] 2023 Oct 31; Vol. 42 (10), pp. 113254. Date of Electronic Publication: 2023 Oct 17.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Antibodies, Monoclonal*
Antibodies, Viral*
Bone Marrow Stromal Antigen 2*/immunology
Ebolavirus*/immunology
Hemorrhagic Fever, Ebola*/virology
Humans ; Antigens, CD ; GPI-Linked Proteins
Czasopismo naukowe
Szczegóły
Tytuł:
Comprehensive profiling of neutralizing polyclonal sera targeting coxsackievirus B3.
Autorzy:
Álvarez-Rodríguez B; Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, 46980, Spain. .
Buceta J; Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, 46980, Spain. .
Geller R; Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, 46980, Spain. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2023 Oct 12; Vol. 14 (1), pp. 6417. Date of Electronic Publication: 2023 Oct 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral*
Antibodies, Neutralizing*
Animals ; Humans ; Mice ; Epitopes ; Serum ; Mutation ; Capsid Proteins
Czasopismo naukowe
Szczegóły
Tytuł:
CurvAGN: Curvature-based Adaptive Graph Neural Networks for Predicting Protein-Ligand Binding Affinity.
Autorzy:
Wu J; Research Center for Graph Computing, Zhejiang Lab, Yuhang, Hangzhou, 311121, Zhejiang, China.
Chen H; Research Center for Graph Computing, Zhejiang Lab, Yuhang, Hangzhou, 311121, Zhejiang, China. .
Cheng M; Department of Computer Science and Engineering, Hong Kong University of Science and Technology, Jiulongwan, Hongkong, 999077, China.
Xiong H; Big Data Lab, Baidu Inc., Haidian, Beijing, 100080, China.
Pokaż więcej
Źródło:
BMC bioinformatics [BMC Bioinformatics] 2023 Oct 05; Vol. 24 (1), pp. 378. Date of Electronic Publication: 2023 Oct 05.
Typ publikacji:
Journal Article
MeSH Terms:
Neutrophils*
Antibodies, Viral*
Ligands ; Drug Discovery ; Neural Networks, Computer
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Maternally transmitted anti-measles antibodies, and susceptibility to disease among infants in Chandigarh, India: A prospective birth cohort study.
Autorzy:
Mathew JL; Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India.
Wagner AL; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America.
Ratho RK; Department of Virology, PGIMER, Chandigarh, India.
Patel PN; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America.
Suri V; Department of Obstetrics and Gynecology, PGIMER, Chandigarh, India.
Bharti B; Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India.
Carlson BF; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America.
Dutta S; Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India.
Singh MP; Department of Virology, PGIMER, Chandigarh, India.
Boulton ML; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America.; Department of Internal Medicine, Division of Infectious Disease, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Oct 03; Vol. 18 (10), pp. e0287110. Date of Electronic Publication: 2023 Oct 03 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral*
Measles*/epidemiology
Measles*/prevention & control
Infant, Newborn ; Humans ; Infant ; Female ; Pregnancy ; Cohort Studies ; Prospective Studies ; Immunity, Maternally-Acquired ; India/epidemiology ; Measles Vaccine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Structural basis for cross-group recognition of an influenza virus hemagglutinin antibody that targets postfusion stabilized epitope.
Autorzy:
Tonouchi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.; Department of Life Science and Medical Bioscience, Waseda University, Shinjuku, Tokyo, Japan.
Adachi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Suzuki T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Kuroda D; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Nishiyama A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics research, National Institutes of Biomedical Innovation, Health and Nutrition; Saito-Asagi, Ibaraki City, Osaka, Japan.
Yumoto K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Takeyama H; Department of Life Science and Medical Bioscience, Waseda University, Shinjuku, Tokyo, Japan.; Computational Bio Big-Data Open Innovation Laboratory (CBBD-OIL), National Institute of Advanced Industrial Science and Technology, Shinjuku, Tokyo, Japan.; Research Organization for Nano and Life Innovation, Waseda University, Shinjuku, Tokyo, Japan.; Institute for Advanced Research of Biosystem Dynamics, Waseda Research Institute for Science and Engineering, Waseda University, Shinjuku, Tokyo, Japan.
Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Hashiguchi T; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2023 Aug 09; Vol. 19 (8), pp. e1011554. Date of Electronic Publication: 2023 Aug 09 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral*/chemistry
Antibodies, Viral*/metabolism
Influenza, Human*
Orthomyxoviridae*
Humans ; Antibodies, Neutralizing ; Epitopes ; Hemagglutinin Glycoproteins, Influenza Virus/chemistry ; Hemagglutinin Glycoproteins, Influenza Virus/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo.
Autorzy:
Hansen L; Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Microbiology, Haukeland University Hospital, Bergen, Norway.
McMahon M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Turner HL; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Zhu X; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Turner JS; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Ozorowski G; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Stadlbauer D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vahokoski J; Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway; National Advisory Unit for Tropical Infectious Diseases, Haukeland University Hospital, Bergen, Norway.
Schmitz AJ; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Rizk AA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Alsoussi WB; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Strohmeier S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yu W; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Choreño-Parra JA; Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico.
Jiménez-Alvarez L; Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
Cruz-Lagunas A; Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
Zúñiga J; Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico.
Mudd PA; Department of Emergency Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Cox RJ; Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Microbiology, Haukeland University Hospital, Bergen, Norway.
Wilson IA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: .
Ward AB; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: .
Ellebedy AH; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: .
Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: .
Pokaż więcej
Źródło:
Immunity [Immunity] 2023 Aug 08; Vol. 56 (8), pp. 1927-1938.e8. Date of Electronic Publication: 2023 Jul 27.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/isolation & purification
Antibodies, Monoclonal*/metabolism
Antibodies, Viral*/isolation & purification
Antibodies, Viral*/metabolism
Influenza A Virus, H1N1 Subtype*
Neuraminidase*/chemistry
Neuraminidase*/metabolism
Influenza, Human*/drug therapy
Humans ; Immunoglobulin Fab Fragments/chemistry ; Cryoelectron Microscopy ; Epitopes ; Mice, Inbred BALB C ; Animals ; Mice ; Disease Models, Animal
Czasopismo naukowe
Szczegóły
Tytuł:
Parvovirus B19 DNA and antibodies in Chinese plasma donors, plasma pools and plasma derivatives.
Autorzy:
Sun P; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Jiang P; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Liu Q; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Zhang R; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Wang Z; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Cao H; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Ye X; Beijing Wantai Biological Pharmacy, Beijing, China.
Ji S; Beijing Wantai Biological Pharmacy, Beijing, China.
Han J; Beijing Wantai Biological Pharmacy, Beijing, China.
Lu K; Chengdu Rongsheng Pharmaceutical Co., Ltd., Chengdu, China.
He X; Chengdu Rongsheng Pharmaceutical Co., Ltd., Chengdu, China.
Fan J; Shandong Taibang Biological Products Co., Ltd., Taian, China.
Cao D; Shandong Taibang Biological Products Co., Ltd., Taian, China.
Zhang Y; Hualan Biological Products Co., Ltd., Xinxiang, China.
Yin Y; Hualan Biological Products Co., Ltd., Xinxiang, China.
Chen Y; Guizhou Taibang Biological Products Co., Ltd, Guiyang, China.
Zhao X; Guizhou Taibang Biological Products Co., Ltd, Guiyang, China.
Ye S; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Su N; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Du X; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Ma L; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Li C; Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.
Pokaż więcej
Źródło:
PeerJ [PeerJ] 2023 Aug 04; Vol. 11, pp. e15698. Date of Electronic Publication: 2023 Aug 04 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
DNA, Viral*/blood
Parvovirus B19, Human*/genetics
Blood Donors*
Antibodies, Viral*/blood
Humans ; East Asian People ; Phylogeny ; Polymerase Chain Reaction ; Seroepidemiologic Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Dynamical changes of SARS-CoV-2 spike variants in the highly immunogenic regions impact the viral antibodies escaping.
Autorzy:
Di Rienzo L; Center for Life Nano-& Neuro-Science, Istituto Italiano di Tecnologia, Rome, Italy.
Miotto M; Center for Life Nano-& Neuro-Science, Istituto Italiano di Tecnologia, Rome, Italy.
Desantis F; Center for Life Nano-& Neuro-Science, Istituto Italiano di Tecnologia, Rome, Italy.; The Open University Affiliated Research Centre at Istituto Italiano di Tecnologia, Genoa, Italy.
Grassmann G; Department of Biochemical Sciences 'Alessandro Rossi Fanelli', Sapienza University of Rome, Rome, Italy.
Ruocco G; Center for Life Nano-& Neuro-Science, Istituto Italiano di Tecnologia, Rome, Italy.; Department of Physics, Sapienza University of Rome, Rome, Italy.
Milanetti E; Center for Life Nano-& Neuro-Science, Istituto Italiano di Tecnologia, Rome, Italy.; Department of Physics, Sapienza University of Rome, Rome, Italy.
Pokaż więcej
Źródło:
Proteins [Proteins] 2023 Aug; Vol. 91 (8), pp. 1116-1129. Date of Electronic Publication: 2023 Apr 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral*
COVID-19*
Humans ; SARS-CoV-2/genetics ; Antibodies, Neutralizing
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Szczegóły
Tytuł:
Construction, expression and assemble of EMCV VLPs and their potency evaluation.
Autorzy:
Zhang H; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China.
Li S; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China.
Su J; College of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, China.
Ma X; College of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, China.
Ali A; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China.
Xie J; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China; College of Life Science and Engineering, Northwest Minzu University, Lanzhou, 730030, China.
Ma Z; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China.
Feng R; Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzhou, 730030, China. Electronic address: .
Pokaż więcej
Źródło:
Virology [Virology] 2023 Jul; Vol. 584, pp. 1-8. Date of Electronic Publication: 2023 May 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral*
Vaccines, Virus-Like Particle*/genetics
Animals ; Mice ; Swine ; Adjuvants, Immunologic ; Antibody Formation
Czasopismo naukowe
Szczegóły
Tytuł:
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
Autorzy:
Carr EJ; The Francis Crick Institute, London, UK; University College London, London, UK.
Wu MY; COVID Surveillance Unit, London, UK; The Francis Crick Institute, London, UK.
Gahir J; The Francis Crick Institute, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility, London, UK.
Harvey R; Worldwide Influenza Centre, London, UK.
Townsley H; The Francis Crick Institute, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility, London, UK.
Bailey C; The Francis Crick Institute, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility, London, UK.
Fowler AS; The Francis Crick Institute, London, UK.
Dowgier G; COVID Surveillance Unit, London, UK.
Hobbs A; COVID Surveillance Unit, London, UK.
Herman L; COVID Surveillance Unit, London, UK.
Ragno M; COVID Surveillance Unit, London, UK.
Miah M; The Francis Crick Institute, London, UK.
Bawumia P; The Francis Crick Institute, London, UK.
Smith C; The Francis Crick Institute, London, UK.
Miranda M; The Francis Crick Institute, London, UK.
Mears HV; The Francis Crick Institute, London, UK.
Adams L; Worldwide Influenza Centre, London, UK.
Haptipoglu E; The Francis Crick Institute, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility, London, UK.
O'Reilly N; The Francis Crick Institute, London, UK.
Warchal S; The Francis Crick Institute, London, UK.
Sawyer C; The Francis Crick Institute, London, UK.
Ambrose K; The Francis Crick Institute, London, UK.
Kelly G; The Francis Crick Institute, London, UK.
Beale R; The Francis Crick Institute, London, UK; University College London, London, UK.
Papineni P; London Northwest University Healthcare NHS Trust, London, UK.
Corrah T; London Northwest University Healthcare NHS Trust, London, UK.
Gilson R; Central and North West London NHS Foundation Trust, London, UK.
Gamblin S; The Francis Crick Institute, London, UK.
Kassiotis G; The Francis Crick Institute, London, UK; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK.
Libri V; University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility, London, UK.
Williams B; University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility, London, UK.
Swanton C; The Francis Crick Institute, London, UK; University College London, London, UK.
Gandhi S; The Francis Crick Institute, London, UK; University College London, London, UK.
Lv Bauer D; The Francis Crick Institute, London, UK.
Wall EC; The Francis Crick Institute, London, UK; University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre and Clinical Research Facility, London, UK. Electronic address: .
Pokaż więcej
Corporate Authors:
Crick COVID Serology Consortium
Źródło:
The Lancet. Infectious diseases [Lancet Infect Dis] 2023 Jul; Vol. 23 (7), pp. 781-784. Date of Electronic Publication: 2023 Jun 05.
Typ publikacji:
Letter
MeSH Terms:
Antibodies, Viral*
SARS-CoV-2*
Vaccines, Combined*
COVID-19 Vaccines*
COVID-19*/immunology
Adult ; Humans ; Antibodies, Neutralizing
SCR Organism:
SARS-CoV-2 variants
Opinia redakcyjna
Szczegóły
Tytuł:
A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Autorzy:
Momont C; Vir Biotechnology, San Francisco, CA, USA.
Dang HV; Vir Biotechnology, San Francisco, CA, USA.
Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Hauser K; Vir Biotechnology, San Francisco, CA, USA.
Wang C; Vir Biotechnology, St. Louis, MO, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Minola A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA.
De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Branch K; Vir Biotechnology, San Francisco, CA, USA.
Donermeyer D; Vir Biotechnology, St. Louis, MO, USA.
Vyas S; Vir Biotechnology, San Francisco, CA, USA.
Chen A; Vir Biotechnology, San Francisco, CA, USA.
Ferri E; Vir Biotechnology, San Francisco, CA, USA.
Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Powell AE; Vir Biotechnology, San Francisco, CA, USA.
Spreafico R; Vir Biotechnology, San Francisco, CA, USA.
Yim SS; Vir Biotechnology, San Francisco, CA, USA.
Balce DR; Vir Biotechnology, San Francisco, CA, USA.
Bartha I; Vir Biotechnology, San Francisco, CA, USA.
Meury M; Vir Biotechnology, San Francisco, CA, USA.
Croll TI; Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK.
Belnap DM; School of Biological Sciences, Department of Biochemistry, University of Utah, Salt Lake City, UT, USA.
Schmid MA; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Schaiff WT; Vir Biotechnology, St. Louis, MO, USA.
Miller JL; Vir Biotechnology, San Francisco, CA, USA.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Telenti A; Vir Biotechnology, San Francisco, CA, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Rosen LE; Vir Biotechnology, San Francisco, CA, USA.
Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Snell G; Vir Biotechnology, San Francisco, CA, USA. .
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2023 Jun; Vol. 618 (7965), pp. 590-597. Date of Electronic Publication: 2023 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/chemistry
Antibodies, Viral*/immunology
Antibodies, Viral*/therapeutic use
Antibody Specificity*/immunology
Influenza A virus*/classification
Influenza A virus*/enzymology
Influenza A virus*/immunology
Influenza B virus*/classification
Influenza B virus*/enzymology
Influenza B virus*/immunology
Influenza Vaccines*/chemistry
Influenza Vaccines*/immunology
Influenza Vaccines*/therapeutic use
Influenza, Human*/immunology
Influenza, Human*/prevention & control
Neuraminidase*/antagonists & inhibitors
Neuraminidase*/chemistry
Neuraminidase*/immunology
Molecular Mimicry*
Animals ; Humans ; Mice ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Arginine/chemistry ; Catalytic Domain ; Hemagglutinins, Viral/immunology ; Influenza A Virus, H3N2 Subtype/enzymology ; Influenza A Virus, H3N2 Subtype/immunology ; Orthomyxoviridae Infections/immunology ; Orthomyxoviridae Infections/prevention & control ; Seasons ; Sialic Acids/chemistry
Czasopismo naukowe
Szczegóły
Tytuł:
Accelerating drug target inhibitor discovery with a deep generative foundation model.
Autorzy:
Chenthamarakshan V; IBM Research, Thomas J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Hoffman SC; IBM Research, Thomas J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Owen CD; Diamond Light Source Ltd., Harwell Science and Innovation Campus, OX11 0DE Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, OX11 0FA Didcot, UK.
Lukacik P; Diamond Light Source Ltd., Harwell Science and Innovation Campus, OX11 0DE Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, OX11 0FA Didcot, UK.
Strain-Damerell C; Diamond Light Source Ltd., Harwell Science and Innovation Campus, OX11 0DE Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, OX11 0FA Didcot, UK.
Fearon D; Diamond Light Source Ltd., Harwell Science and Innovation Campus, OX11 0DE Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, OX11 0FA Didcot, UK.
Malla TR; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, OX1 3TA Oxford, UK.
Tumber A; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, OX1 3TA Oxford, UK.
Schofield CJ; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, OX1 3TA Oxford, UK.
Duyvesteyn HME; Division of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Carrique L; Division of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Walter TS; Division of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Screaton GR; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Matviiuk T; Enamine Ltd., Chervonotkatska St, 67, Kyiv 02094, Ukraine.
Mojsilovic A; IBM Research, Thomas J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Crain J; IBM Research Europe, Hartree Centre, Daresbury WA4 4AD, UK.; Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK.
Walsh MA; Diamond Light Source Ltd., Harwell Science and Innovation Campus, OX11 0DE Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, OX11 0FA Didcot, UK.
Stuart DI; Diamond Light Source Ltd., Harwell Science and Innovation Campus, OX11 0DE Didcot, UK.; Division of Structural Biology, University of Oxford, The Wellcome Centre for Human Genetics, Headington, Oxford, UK.
Das P; IBM Research, Thomas J. Watson Research Center, Yorktown Heights, New York, NY, USA.
Pokaż więcej
Źródło:
Science advances [Sci Adv] 2023 Jun 23; Vol. 9 (25), pp. eadg7865. Date of Electronic Publication: 2023 Jun 21.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/chemistry
COVID-19*
Humans ; SARS-CoV-2/metabolism ; Protein Binding ; Amino Acid Sequence
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 42992

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies